Verastem Oncology says Gynecologic Oncology published RAMP 201 follow-up data

The company said the journal published two-year follow-up data from its Phase 2 RAMP 201 study of AVMAPKI FAKZYNJA CO-PACK in recurrent low-grade serous ovarian cancer. Verastem cited median duration of response of 31.1 months and no new safety signals.